The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon ...
Finally, there are many risks associated with longer stays: infections; blood clots; muscle weakening and pressure sores, to ...
The Briefing Room – what next for healthcare communications?
The approvals are supported by the REAL8 study, which showed Sogroya was non‑inferior to daily growth hormone therapy across all three indications. Adverse reactions occurring in at least 10% of ...
HUTCHMED has initiated a global phase 1/2a clinical trial of HMPL‑A580, its second antibody‑targeted therapy conjugate, in ...
Bioxytran has announced encouraging results from a randomized, double‑blind, placebo‑controlled phase 1b/2a study of its oral ...
Sexual health, personality disorders, incontinence, infertility, addiction, end-of-life care and chronic pain are some of the messy, painful and complicated realities of being human. Too often, people ...
The arrival of ChatGPT as a mass consumer tool, available to anyone with a smartphone or a PC in November 2023, heralded a new Armageddon scenario for the global employment market. The fear that ...
For decades, the UK’s pharmaceutical and biotech sectors have been leaders in discovery and innovation. Yet as the cost of bringing innovation to market increases and global competition intensifies, ...
The NHS in 2026 is facing a familiar but intensifying oncology challenge. Our data at HSJ Information shows rising incidence, workforce strain, diagnostic bottlenecks and stark inequalities in ...
AlzeCure Pharma has announced that the European Medicines Agency has granted orphan drug status to ACD440, its clinical‑stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results